Chronic Lymphocytic Leukemia
January 2017 Issue
 
 
 

Nearly every major medical breakthrough over the past 50 years can be attributed to new discoveries that were made possible through meticulous biomedical research. Many diseases and conditions that previously took a heavy toll on patients in terms of both morbidity and mortality are now either treatable or preventable thanks in large part to painstaking research that expanded the frontiers of scientific knowledge and moved the most promising basic research developments into tangible health benefits through human clinical trails. Ongoing research is also the key that will open the door to additional major medical advances and breakthroughs in the future.

Our staff at Medifocus is committed to keeping our subscribers to the Medifocus Digest Alert on Chronic Lymphocytic Leukemia abreast of the latest new research developments that have recently been published in the medical literature for this condition. In this issue of the Digest Alert, you will find a focused list of hand-picked journal article references that represent the latest advances in basic and clinical research for Chronic Lymphocytic Leukemia. These articles represent the current state-of-the-art of the research that will hopefully lead to additional major advances and breakthroughs in the clinical management of Chronic Lymphocytic Leukemia. You can access the summaries of each article referenced below by simply clicking on the article Title.

We will continue to update you with the latest scientific and clinical developments through the Medifocus Digest Alert on Chronic Lymphocytic Leukemia every 3 months. Thank you for your ongoing subscription to this publication.

Sincerely,
Elliot Jacob, Ph.D.
Vice-President - Content
Medifocus.com, Inc.



1:Allogeneic Transplantation for Chronic Lymphocytic Leukemia in the Age of Novel Treatment Strategies.
Authors:Schwarzbich MA, McClanahan F, Gribben J
Journal:Oncology (Williston Park). 2016 Jun;30(6):526-33, 540.

2:Venetoclax: Bcl-2 inhibition for the treatment of chronic lymphocytic leukemia.
Authors:Del Poeta G, Postorino M, Pupo L, Del Principe MI, Dal Bo M, Bittolo T, Buccisano F, Mariotti B, Iannella E, Maurillo L, Venditti A, Gattei V, de Fabritiis P, Cantonetti M, Amadori S
Institution:Hematology, Dipartimento di Biomedicina e Prevenzione, Universit a degli Studi di Roma Tor Vergata, Rome, Italy. g.delpoeta@tin.it.; Clinical and Experimental Onco-Hematology Unit, Centro di Riferimento Oncologico, I.R.C.C.S., Aviano (PN), Italy.
Journal:Drugs Today (Barc). 2016 Apr;52(4):249-60. doi: 10.1358/dot.2016.52.4.2470954.

3:Ibrutinib (Imbruvica). Relapsed chronic lymphocytic leukaemia and mantle cell lymphoma: uncertain impact on survival.
Authors:January
Journal:Prescrire Int. 2016 Apr;25(170):89-92.

4:Novel Biomarker Proteins in Chronic Lymphocytic Leukemia: Impact on Diagnosis, Prognosis and Treatment.
Authors:Admoni-Elisha L, Nakdimon I, Shteinfer A, Prezma T, Arif T, Arbel N, Melkov A, Zelichov O, Levi I, Shoshan-Barmatz V
Institution:Department of Life Sciences and the National Institute for Biotechnology in the Negev, Ben-Gurion University of the Negev, Beer Sheva, Israel.; Department of Hematology, Soroka University Medical Center and the Faculty of Health Sciences, Ben-Gurion University of the Negev, Beer Sheva, Israel.
Journal:PLoS One. 2016 Apr 14;11(4):e0148500. doi: 10.1371/journal.pone.0148500. eCollection 2016.

5:Richter syndrome: pathogenesis and management.
Authors:Rossi D, Gaidano G
Institution:Division of Hematology, Department of Translational Medicine, Amedeo Avogadro University of Eastern Piedmont, Novara, Italy. Electronic address: rossidav@med.unipmn.it.
Journal:Semin Oncol. 2016 Apr;43(2):311-9. doi: 10.1053/j.seminoncol.2016.02.012. Epub 2016 Feb 15.

6:Secondary autoimmune cytopenias in chronic lymphocytic leukemia.
Authors:Rogers KA, Woyach JA
Institution:Division of Hematology, Department of Internal Medicine, The Ohio State University, Columbus, OH. University, Columbus, OH. Electronic address: Jennifer.woyach@osumc.edu.
Journal:Semin Oncol. 2016 Apr;43(2):300-10. doi: 10.1053/j.seminoncol.2016.02.011. Epub 2016 Feb 8.

7:Improving therapy of chronic lymphocytic leukemia with chimeric antigen receptor T cells.
Authors:Fraietta JA, Schwab RD, Maus MV
Institution:Center for Cellular Immunotherapy, Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA. Pennsylvania, Philadelphia, PA. Harvard Medical School, Boston, MA. Electronic address: mvmaus@mgh.harvard.edu.
Journal:Semin Oncol. 2016 Apr;43(2):291-9. doi: 10.1053/j.seminoncol.2016.02.006. Epub 2016 Feb 9.

8:Antibody therapy alone and in combination with targeted drugs in chronic lymphocytic leukemia.
Authors:Robak T, Blonski JZ, Robak P
Institution:Department of Hematology, Medical University of Lodz, Lodz, Poland. Electronic address: robaktad@csk.umed.lodz.pl.
Journal:Semin Oncol. 2016 Apr;43(2):280-90. doi: 10.1053/j.seminoncol.2016.02.010. Epub 2016 Feb 8.

9:Progress in BCL2 inhibition for patients with chronic lymphocytic leukemia.
Authors:Tam CS, Seymour JF, Roberts AW
Institution:Haematology Department, Peter MacCallum Cancer Center, East Melbourne, Victoria, Australia; University of Melbourne, Parkville, Victoria, Australia. Electronic address: constantine.tam@petermac.org. Australia; University of Melbourne, Parkville, Victoria, Australia. Haematology and BMT, Royal Melbourne Hospital, Parkville, Victoria, Australia; Cancer and Haematology Division, Walter and Eliza Hall Institute of Medical Research, Parkville, Victoria, Australia.
Journal:Semin Oncol. 2016 Apr;43(2):274-9. doi: 10.1053/j.seminoncol.2016.02.014. Epub 2016 Feb 6.

10:Cyclin-dependent kinase inhibitors for the treatment of chronic lymphocytic leukemia.
Authors:Blachly JS, Byrd JC, Grever M
Institution:Division of Hematology, Department of Medicine, The Ohio State University, Columbus, OH; The Ohio State University James Comprehensive Cancer Center, Columbus, OH. Electronic address: james.blachly@osumc.edu.
Journal:Semin Oncol. 2016 Apr;43(2):265-73. doi: 10.1053/j.seminoncol.2016.02.003. Epub 2016 Feb 8.

11:The PI3K pathway: clinical inhibition in chronic lymphocytic leukemia.
Authors:Brown JR
Institution:CLL Center, Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA; Department of Medicine, Harvard Medical School, Boston, MA. Electronic address: jbrown2@partners.org.
Journal:Semin Oncol. 2016 Apr;43(2):260-4. doi: 10.1053/j.seminoncol.2016.02.004. Epub 2016 Feb 8.

12:Bruton tyrosine kinase inhibition in chronic lymphocytic leukemia.
Authors:Maddocks K, Jones JA
Institution:The Ohio State University Comprehensive Cancer Center, Arthur G James Comprehensive Cancer Center, Columbus, OH. Electronic address: kami.maddocks@osumc.edu. Comprehensive Cancer Center, Columbus, OH.
Journal:Semin Oncol. 2016 Apr;43(2):251-9. doi: 10.1053/j.seminoncol.2016.02.008. Epub 2016 Feb 9.

13:Initial therapy of chronic lymphocytic leukemia.
Authors:Eichhorst B, Cramer P, Hallek M
Institution:Department I for Internal Medicine and Center of Integrated Oncology, University of Cologne, Cologne, Germany. Electronic address: barbara.eichhorst@uk-koeln.de. Aging-associated Diseases. of Cologne, Cologne, Germany; CECAD-Cologne Cluster of Excellence in Cellular Stress Responses in Aging-associated Diseases.
Journal:Semin Oncol. 2016 Apr;43(2):241-50. doi: 10.1053/j.seminoncol.2016.02.005. Epub 2016 Feb 9.

14:Prognostic factors and risk stratification in chronic lymphocytic leukemia.
Authors:Parikh SA, Shanafelt TD
Institution:Division of Hematology, Department of Medicine, Mayo Clinic, Rochester, MN. Electronic address: shanafelt.tait@mayo.edu.
Journal:Semin Oncol. 2016 Apr;43(2):233-40. doi: 10.1053/j.seminoncol.2016.02.009. Epub 2016 Feb 8.

15:Gene mutations in chronic lymphocytic leukemia.
Authors:Amin NA, Malek SN
Institution:Department of Internal Medicine, Division of Hematology and Oncology, University of Michigan, Ann Arbor, MI, USA. of Michigan, Ann Arbor, MI, USA. Electronic address: smalek@med.umich.edu.
Journal:Semin Oncol. 2016 Apr;43(2):215-21. doi: 10.1053/j.seminoncol.2016.02.002. Epub 2016 Feb 6.

16:The clinical implications of gene mutations in chronic lymphocytic leukaemia.
Authors:Rossi D, Gaidano G
Institution:Department of Hematology, Oncology Institute of Southern Switzerland and Institute of Oncology Research, 6500 Bellinzona, Switzerland. University of Eastern Piedmont, 28100 Novara, Italy.
Journal:Br J Cancer. 2016 Apr 12;114(8):849-54. doi: 10.1038/bjc.2016.78. Epub 2016 Mar 31.

17:Trends in survival of chronic lymphocytic leukemia patients in Germany and the USA in the first decade of the twenty-first century.
Authors:Pulte D, Castro FA, Jansen L, Luttmann S, Holleczek B, Nennecke A, Ressing M, Katalinic A, Brenner H
Institution:Division of Clinical Epidemiology and Aging Research, German Cancer Research Center (DKFZ), Im Neuenheimer Feld 581, 69121, Heidelberg, Germany. pultedi@gmail.com.; Cardeza Foundation and Division of Hematology, Department of Medicine, Thomas Jefferson University, Philadelphia, PA, USA. pultedi@gmail.com.; Bremen Cancer Registry, Leibniz-Institute for Prevention Research and Epidemiology-BIPS, Bremen, Germany.; Saarland Cancer Registry, Saarbrucken, Germany.; Hamburg Cancer Registry, Authority for Health and Consumer Protection, Hamburg, Germany.
Journal:J Hematol Oncol. 2016 Mar 22;9:28. doi: 10.1186/s13045-016-0257-2.

18:Lenalidomide treatment and prognostic markers in relapsed or refractory chronic lymphocytic leukemia: data from the prospective, multicenter phase-II CLL-009 trial.
Authors:Buhler A, Wendtner CM, Kipps TJ, Rassenti L, Fraser GA, Michallet AS, Hillmen P, Durig J, Gregory SA, Kalaycio M, Aurran-Schleinitz T, Trentin L, Gribben JG, Chanan-Khan A, Purse B, Zhang J, De Bedout S, Mei J, Hallek M, Stilgenbauer S
Institution:Department of Internal Medicine III, Ulm University, Ulm, Germany. Germany. Diseases (CECAD), Cologne, Germany.
Journal:Blood Cancer J. 2016 Mar 11;6:e404. doi: 10.1038/bcj.2016.9.

19:Bendamustine + rituximab chemoimmunotherapy and maintenance lenalidomide in relapsed, refractory chronic lymphocytic leukaemia and small lymphocytic lymphoma: A Wisconsin Oncology Network Study.
Authors:Chang JE, Havighurst T, Kim K, Eickhoff J, Traynor AM, Kirby-Slimp R, Volk LM, Werndli J, Go RS, Weiss M, Blank J, Kahl BS
Institution:Department of Medicine, University of Wisconsin School of Medicine and Public Health and the UW Carbone Cancer Center, Madison, WI, USA. Madison, WI, USA. Madison, WI, USA. Madison, WI, USA. Health and the UW Carbone Cancer Center, Madison, WI, USA. Cancer Center, Madison, WI, USA. Cancer Center, Madison, WI, USA. Cancer Center, Madison, WI, USA. USA.
Journal:Br J Haematol. 2016 Apr;173(2):283-91. doi: 10.1111/bjh.13957. Epub 2016 Feb 23.

20:The molecular pathogenesis of chronic lymphocytic leukaemia.
Authors:Fabbri G, Dalla-Favera R
Institution:Institute for Cancer Genetics, Columbia University, New York, New York 10032, USA. York 10032, USA. USA. York 10032, USA. University, New York, New York 10032, USA.
Journal:Nat Rev Cancer. 2016 Mar;16(3):145-62. doi: 10.1038/nrc.2016.8.

21:Should IGHV status and FISH testing be performed in all CLL patients at diagnosis? A systematic review and meta-analysis.
Authors:Parikh SA, Strati P, Tsang M, West CP, Shanafelt TD
Institution:Division of Hematology and. Biomedical Statistics and Informatics, Department of Health Sciences Research, Mayo Clinic, Rochester, MN.
Journal:Blood. 2016 Apr 7;127(14):1752-60. doi: 10.1182/blood-2015-10-620864. Epub 2016 Feb 3.

22:Combination of Targeted Drugs to Control Chronic Lymphocytic Leukemia: Harnessing the Power of New Monoclonal Antibodies in Combination With Ibrutinib.
Authors:Cramer P, Langerbeins P, Hallek M
Institution:From the *Department I of Internal Medicine, Center of Integrated Oncology Cologne-Bonn and German CLL Study Group, University of Cologne; and daggerCECAD-Cologne Cluster of Excellence in Cellular Stress Responses in Aging-Associated Diseases, Cologne, Germany.
Journal:Cancer J. 2016 Jan-Feb;22(1):62-6. doi: 10.1097/PPO.0000000000000174.

23:Ibrutinib as a Bruton Kinase Inhibitor in the Management of Chronic Lymphocytic Leukemia: A New Agent With Great Promise.
Authors:Foluso O, Glick A, Stender M, Jaiyesimi I
Institution:Department of Hematology and Oncology, Oakland University, William Beaumont School of Medicine, William Beaumont Health System, Royal Oak, MI. Electronic address: Ogunleye.Foluso@beaumont.edu.
Journal:Clin Lymphoma Myeloma Leuk. 2016 Feb;16(2):63-9. doi: 10.1016/j.clml.2015.11.011. Epub 2015 Nov 22.

24:Obinutuzumab: the more the merrier?
Authors:Burger JA
Institution:THE UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER.
Journal:Blood. 2016 Jan 7;127(1):6-8. doi: 10.1182/blood-2015-10-676882.

25:Venetoclax Yields Strong Responses in CLL.
Authors:
Journal:Cancer Discov. 2016 Feb;6(2):113-4. doi: 10.1158/2159-8290.CD-NB2015-180. Epub 2015 Dec 23.

26:Chronic lymphocytic leukemia (CLL)-Then and now.
Authors:Rai KR, Jain P
Institution:Division of Hematology-Oncology, NSLIJ-Hofstra School of Medicine, Long Island Jewish Medical Center, CLL Research and Treatment Program, New Hyde Park, New York. Texas.
Journal:Am J Hematol. 2016 Mar;91(3):330-40. doi: 10.1002/ajh.24282.

27:A phase II randomized trial comparing standard and low dose rituximab combined with alemtuzumab as initial treatment of progressive chronic lymphocytic leukemia in older patients: a trial of the ECOG-ACRIN cancer research group (E1908).
Authors:Zent CS, Victoria Wang X, Ketterling RP, Hanson CA, Libby EN, Barrientos JC, Call TG, Chang JE, Liu JJ, Calvo AR, Lazarus HM, Rowe JM, Luger SM, Litzow MR, Tallman MS
Institution:University of Rochester Medical Center, Rochester, New York (Current Location) Mayo Clinic, Rochester, Minnesota (Former Location). Massachusetts. of New Mexico Cancer Center, Albuquerque, NM. Northwestern University School of Medicine, Chicago, Illinois (Former Location).
Journal:Am J Hematol. 2016 Mar;91(3):308-12. doi: 10.1002/ajh.24265. Epub 2016 Feb 9.

28:Ibrutinib combined with bendamustine and rituximab compared with placebo, bendamustine, and rituximab for previously treated chronic lymphocytic leukaemia or small lymphocytic lymphoma (HELIOS): a randomised, double-blind, phase 3 study.
Authors:Chanan-Khan A, Cramer P, Demirkan F, Fraser G, Silva RS, Grosicki S, Pristupa A, Janssens A, Mayer J, Bartlett NL, Dilhuydy MS, Pylypenko H, Loscertales J, Avigdor A, Rule S, Villa D, Samoilova O, Panagiotidis P, Goy A, Mato A, Pavlovsky MA, Karlsson C, Mahler M, Salman M, Sun S, Phelps C, Balasubramanian S, Howes A, Hallek M
Institution:Mayo Clinic Cancer Center, Jacksonville, FL, USA. Electronic address: Chanan-Khan.Asher@mayo.edu.; Department I of Internal Medicine and German CLL Study Group, University of Cologne, Cologne, Germany.; Division of Hematology, Dokuz Eylul University, Izmir, Turkey.; Juravinski Cancer Centre, McMaster University, Hamilton, ON, Canada.; IEP Sao Lucas/Hemomed Oncologia e Hematologia, Sao Paulo, Brazil.
Journal:Lancet Oncol. 2016 Feb;17(2):200-11. doi: 10.1016/S1470-2045(15)00465-9. Epub 2015 Dec 5.

29:Acalabrutinib (ACP-196) in Relapsed Chronic Lymphocytic Leukemia.
Authors:Byrd JC, Harrington B, O'Brien S, Jones JA, Schuh A, Devereux S, Chaves J, Wierda WG, Awan FT, Brown JR, Hillmen P, Stephens DM, Ghia P, Barrientos JC, Pagel JM, Woyach J, Johnson D, Huang J, Wang X, Kaptein A, Lannutti BJ, Covey T, Fardis M, McGreivy J, Hamdy A, Rothbaum W, Izumi R, Diacovo TG, Johnson AJ, Furman RR
Institution:From the Division of Hematology, Department of Internal Medicine, Ohio State University (J.C. Byrd, J.A.J., F.T.A., J.W., A.J.J.), and the Department of Veterinary Biosciences, College of Veterinary Medicine (B.H.) - both in Columbus; UC Irvine Health Chao Family Comprehensive Cancer Center, University of California, Irvine, Orange (S.O.); University of Oxford, Oxford (A.S.), NHS Foundation Trust, King's College Hospital, London (S.D.), and the Department of Haematology, St. James's University Hospital, Leeds (P.H.) - all in the United Kingdom; Northwest Medical Specialties, Tacoma (J.C.), and the Swedish Cancer Institute, Seattle (J.M.P.) - both in Washington; the Department of Leukemia, Division of Cancer Medicine, University of Texas, and M.D. Anderson Cancer Center - both in Houston (W.G.W.); the Department of Medical Oncology, Dana-Farber Cancer Institute, Boston (J.R.B.); Huntsman Cancer Institute, University of Utah, Salt Lake City (D.M.S.); Universita Vita-Salute San Raffaele and Istituto Scientifico San Raffaele, Milan (P.G.); Hofstra North Shore-LIJ School of Medicine, Chronic Lymphocytic Leukemia Research and Treatment Center, Lake Success (J.C. Barrientos), and the Department of Pathology and Cell Biology, Columbia University Medical Center (T.G.D.), and New York-Presbyterian/Weill Cornell Medical Center, New York (R.R.F.) - all in New York; and Acerta Pharma, Oss, the Netherlands (D.J., J.H., X.W., A.K., B.J.L., T.C., M.F., J.M., A.H., W.R., R.I.).
Journal:N Engl J Med. 2016 Jan 28;374(4):323-32. doi: 10.1056/NEJMoa1509981. Epub 2015 Dec 7.

30:Targeting BCL2 with Venetoclax in Relapsed Chronic Lymphocytic Leukemia.
Authors:Roberts AW, Davids MS, Pagel JM, Kahl BS, Puvvada SD, Gerecitano JF, Kipps TJ, Anderson MA, Brown JR, Gressick L, Wong S, Dunbar M, Zhu M, Desai MB, Cerri E, Heitner Enschede S, Humerickhouse RA, Wierda WG, Seymour JF
Institution:From the Department of Clinical Haematology and the Bone Marrow Transplantation Unit, Royal Melbourne Hospital (A.W.R., M.A.A.), the Division of Cancer and Haematology, Walter and Eliza Hall Institute of Medical Research (A.W.R., M.A.A.), and the Victorian Comprehensive Cancer Centre (A.W.R., J.F.S.), Parkville, VIC, and the University of Melbourne (A.W.R., J.F.S.) and Peter MacCallum Cancer Centre (J.F.S.), Melbourne, VIC - all in Australia; Dana-Farber Cancer Institute, Boston (M.S.D., J.R.B.); the Swedish Medical Center, Seattle (J.M.P.); Washington University, St. Louis (B.S.K.); University of Arizona, Tucson (S.D.P.); Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College, New York (J.F.G.); University of California, San Diego, San Diego (T.J.K.); AbbVie, North Chicago, IL (L.G., S.W., M.D., M.Z., M.B.D., E.C., S.H.E., R.A.H.); and University of Texas M.D. Anderson Cancer Center, Houston (W.G.W.).
Journal:N Engl J Med. 2016 Jan 28;374(4):311-22. doi: 10.1056/NEJMoa1513257. Epub 2015 Dec 6.

31:Chronic Lymphocytic Leukemia and Other Lymphoproliferative Disorders.
Authors:Wall S, Woyach JA
Institution:Division of Hematology, Department of Internal Medicine, The Ohio State University Comprehensive Cancer Center, 445A Wiseman Hall, 410 West 12th Avenue, Columbus, OH 43210, USA. Electronic address: Jennifer.Woyach@osumc.edu.
Journal:Clin Geriatr Med. 2016 Feb;32(1):175-89. doi: 10.1016/j.cger.2015.08.006.

32:Eliminating minimal residual disease as a therapeutic end point: working toward cure for patients with CLL.
Authors:Thompson PA, Wierda WG
Institution:Department of Leukemia, University of Texas M.D. Anderson Cancer Center, Houston, TX. TX.
Journal:Blood. 2016 Jan 21;127(3):279-86. doi: 10.1182/blood-2015-08-634816. Epub 2015 Nov 17.

33:Fludarabine, cyclophosphamide, and rituximab treatment achieves long-term disease-free survival in IGHV-mutated chronic lymphocytic leukemia.
Authors:Thompson PA, Tam CS, O'Brien SM, Wierda WG, Stingo F, Plunkett W, Smith SC, Kantarjian HM, Freireich EJ, Keating MJ
Institution:Department of Leukemia, University of Texas MD Anderson Cancer Center, Houston, TX; Melbourne, Australia; TX; TX; Center, Houston, TX. TX; TX; TX; TX;
Journal:Blood. 2016 Jan 21;127(3):303-9. doi: 10.1182/blood-2015-09-667675. Epub 2015 Oct 22.

34:Long-term remissions after FCR chemoimmunotherapy in previously untreated patients with CLL: updated results of the CLL8 trial.
Authors:Fischer K, Bahlo J, Fink AM, Goede V, Herling CD, Cramer P, Langerbeins P, von Tresckow J, Engelke A, Maurer C, Kovacs G, Herling M, Tausch E, Kreuzer KA, Eichhorst B, Bottcher S, Seymour JF, Ghia P, Marlton P, Kneba M, Wendtner CM, Dohner H, Stilgenbauer S, Hallek M
Institution:Department I for Internal Medicine and Center of Integrated Oncology, University of Cologne, Cologne, Germany; Department of Hematology, Oncology, Immunology, Palliative Care, Infectious Diseases and Tropical Medicine, Klinikum Schwabing, Munich, Germany; and.; Department of Internal Medicine III, University of Ulm, Ulm, Germany;; Department of Internal Medicine II, University Hospital of Schleswig-Holstein, Kiel, Germany;; Peter MacCallum Cancer Centre and University of Melbourne, Melbourne, Australia;; Division of Experimental Oncology and Department of Onco-Hematology, Universita Vita-Salute San Raffaele and Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) Istituto Scientifico San Raffaele, Milano, Italy;
Journal:Blood. 2016 Jan 14;127(2):208-15. doi: 10.1182/blood-2015-06-651125. Epub 2015 Oct 20.

35:Randomized phase 2 study of obinutuzumab monotherapy in symptomatic, previously untreated chronic lymphocytic leukemia.
Authors:Byrd JC, Flynn JM, Kipps TJ, Boxer M, Kolibaba KS, Carlile DJ, Fingerle-Rowson G, Tyson N, Hirata J, Sharman JP
Institution:Division of Hematology and Comprehensive Cancer Center and Division of Medicinal Chemistry, College of Pharmacy, The Ohio State University, Columbus, OH; Research Center, Eugene, OR.
Journal:Blood. 2016 Jan 7;127(1):79-86. doi: 10.1182/blood-2015-03-634394. Epub 2015 Oct 15.

36:The long-term outcome of patients in the LRF CLL4 trial: the effect of salvage treatment and biological markers in those surviving 10 years.
Authors:Else M, Wade R, Oscier D, Catovsky D
Institution:Division of Molecular Pathology, The Institute of Cancer Research, London, UK.
Journal:Br J Haematol. 2016 Jan;172(2):228-37. doi: 10.1111/bjh.13824. Epub 2015 Oct 12.

37:Incidence and description of autoimmune cytopenias during treatment with ibrutinib for chronic lymphocytic leukemia.
Authors:Rogers KA, Ruppert AS, Bingman A, Andritsos LA, Awan FT, Blum KA, Flynn JM, Jaglowski SM, Lozanski G, Maddocks KJ, Byrd JC, Woyach JA, Jones JA
Institution:Division of Hematology, The Ohio State University, Columbus, OH, USA.
Journal:Leukemia. 2016 Feb;30(2):346-50. doi: 10.1038/leu.2015.273. Epub 2015 Oct 7.

38:Advances in first-line treatment of chronic lymphocytic leukemia: current recommendations on management and first-line treatment by the German CLL Study Group (GCLLSG).
Authors:Cramer P, Langerbeins P, Eichhorst B, Hallek M
Institution:Department I of Internal Medicine, Center of Integrated Oncology Cologne-Bonn and German CLL Study Group, University of Cologne, Cologne, Germany.; CECAD - Cologne Cluster of Excellence in Cellular Stress Responses in Aging-associated Diseases, University of Cologne, Cologne, Germany.
Journal:Eur J Haematol. 2016 Jan;96(1):9-18. doi: 10.1111/ejh.12678. Epub 2015 Nov 6.

39:Two distinct molecular subtypes of chronic lymphocytic leukemia give new insights on the pathogenesis of the disease and identify novel therapeutic targets.
Authors:Cordoba R, Sanchez-Beato M, Herreros B, Domenech E, Garcia-Marco J, Garcia JF, Martinez-Lopez J, Rodriguez A, Garcia-Raso A, Llamas P, Piris MA
Institution:a Lymphoma Unit, Fundacion Jimenez Diaz University Hospital, Health Research Institute IIS-FJD , Madrid , Spain. , Madrid , Spain. Spain. Spain. Spain. , Madrid , Spain. Institute IIS-FJD , Madrid , Spain. Institute IIS-FJD , Madrid , Spain. Spain.
Journal:Leuk Lymphoma. 2016;57(1):134-42. doi: 10.3109/10428194.2015.1034706. Epub 2015 May 12.

40:A review of a novel, Bruton's tyrosine kinase inhibitor, ibrutinib.
Authors:Lee CS, Rattu MA, Kim SS
Institution:Department of Pharmacy, The Mount Sinai Hospital, New York, NY, USA leec3@stjohns.edu.
Journal:J Oncol Pharm Pract. 2016 Feb;22(1):92-104. doi: 10.1177/1078155214561281. Epub 2014 Nov 25.

For a FREE PREVIEW of the Medifocus Guidebook on Chronic Lymphocytic Leukemia click here

To purchase a copy of the COMPLETE Medifocus Guidebook on Chronic Lymphocytic Leukemia click here

To subscribe to additional FREE Medifocus Digest Alert on other disease/condition areas click here

  
Get the Medifocus Guidebook on Chronic Lymphocytic Leukemia...
at a Special 20% Discount


Medifocus Guidebook on Chronic Lymphocytic Leukemia

Updated: January 22, 2017
181 Pages

This one of a kind Guidebook offers:

  • Answers to your critical health questions including the latest treatments, clinical trials, and expert research.
     
  • High Quality, Professional level information you can trust and understand culled from the latest peer-reviewed journals.
     
  • Timely, up to date content with free guidebook updates for 1 year.
     
  • A unique resource to find leading experts, institutions, and support organizations including contact information and hyperlinks.
     
  • Over 130,000 Guidebooks Sold
     
  • 100% Risk Free Money Back Guarantee



ORDER THE GUIDEBOOK

The Medifocus Guidebook on Chronic Lymphocytic Leukemia is available in the following two convenient formats:

PRINTED GUIDEBOOK

Soft-cover book that is available for immediate shipping via either U.S. Priority Mail or International AirMail (outside the U.S.).

  • Regular List Price = $36.95
  • Less 20% Discount = - $7.40
  • Discounted Price = $29.55(excluding shipping & handling)

Order the Printed Guidebook

DIGITAL GUIDEBOOK

Available for immediate download as a PDF document.

  • Regular List Price = $27.95
  • Less 20% Discount = - $5.60
  • Discounted Price = $22.35

Order the Digital Guidebook



Order by Phone

Call Toll Free in the U.S.
1-800-965-3002

From Outside the U.S.
1-301-649-9300

You can also receive a 20% discount when you order your Guidebook by phone.

To receive your 20% discount, simply mention the Discount Coupon Code below to the customer service representative taking your order.

Discount Coupon Code for
Phone Orders

CL92357823

Coupon Expires: April 25, 2017



What Our Customers Are Saying...

"I was recently diagnosed with CLL and searched all over the Web for information. I found the MediFocus Guidebook on Chronic Lymphocytic Leukemia to be a very useful resource. The information about chemotherapy was most important to me as well as recent studies concerning general treatments for this condition. The most valuable information was contained in the extensive references listed which were easy to access with a simple 'mouse' click. You are welcome to use my name as a reference."
G.C.
Coedpoeth, United Kingdom



  
Medifocus Digest Alert is published monthly by Medifocus, Inc.
6810 Park Heights Avenue, Suite C5, Baltimore, MD 21215 USA
Copyright © 2013 Medifocus, Inc. All rights reserved.